Obesity Medicines Approved in the EU (EMA)

• 13medicines authorised in the EU (authorised now)

Each number has its full source under its own list below.

• 15Jul2026

  Ablymico

  Active substance: liraglutide

  EMEA/H/C/006620
• 15Sep2022

  Mounjaro

  Active substance: tirzepatide

  EMEA/H/C/005620
• 6Jan2022

  Wegovy

  Active substance: semaglutide

  EMEA/H/C/005422
• 16Jul2021

  Imcivree

  Active substance: setmelanotide

  EMEA/H/C/005089
• 26Mar2015

  Mysimba

  Active substance: bupropion hydrochloride;naltrexone hydrochloride

  EMEA/H/C/003687
• 23Mar2015

  Saxenda

  Active substance: liraglutide

  EMEA/H/C/003780
• 19Sep2013

  Incresync

  Active substance: alogliptin;pioglitazone

  EMEA/H/C/002178
• 21Mar2012

  Pioglitazone Accord

  Active substance: pioglitazone hydrochloride

  EMEA/H/C/002277
• 15Mar2012

  Pioglitazone Actavis

  Active substance: pioglitazone hydrochloride

  EMEA/H/C/002324
• 22Jul2007

  Alli (previously Orlistat GSK)

  Active substance: orlistat

  EMEA/H/C/000854
• 28Jul2006

  Competact

  Active substance: pioglitazone;metformin hydrochloride

  EMEA/H/C/000655
• 13Oct2000

  Actos

  Active substance: pioglitazone hydrochloride

  EMEA/H/C/000285
• 29Jul1998

  Xenical

  Active substance: orlistat

  EMEA/H/C/000154

Source: European Medicines Agency, Centrally authorised human medicines (EPAR), authorised now. Retrieved 12 Nov 2026.

• Obesity (adults)
• Clinical trials: Obesity
• Obesity (adults)

• Diabetes
• Pediatric
• Aesthetics
• Liver health
• Cardiovascular
• Maternal